At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRTX Galera Therapeutics, Inc.
Pre-Market Trading 05-16 04:21:40 EDT
0.1900
+0.0149
+8.51%
High0.1900
Low0.1760
Vol415.21K
Open0.1783
D1 Closing0.1751
Amplitude8.00%
Mkt Cap10.33M
Tradable Cap7.49M
Total Shares54.39M
T/O75.48K
T/O Rate1.05%
Tradable Shares39.42M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Galera Therapeutics Had Cash And Cash Equivalents Of $13.5M Expected To Provide Cash Runway Into Q3 2025
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.